(Q27631791)

1

0 references

T L Johnson

2

0 references

J Liu

3

0 references

J K Muckelbauer

4

0 references

R H Grafstrom

5

0 references

S Cox

6

0 references

J Boylan

7

0 references

C R Burton

8

0 references

H Chen

9

0 references

A Smallwood

10

0 references

C H Chang

11

0 references

M Boisclair

12

0 references

P A Benfield

13

0 references

G L Trainor

14

0 references

S P Seitz

Bioorganic & Medicinal Chemistry Letters

15

0 references

language of work or name

English

0 references

publication date

7 May 2001

0 references

published in

0 references

volume

11

0 references

issue

9

0 references

page(s)

1157-60

0 references

cites work

Cyclins and cyclin-dependent kinases: theme and variations

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Crystal structure of cyclin-dependent kinase 2

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Purification and crystallization of human cyclin-dependent kinase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Processing of X-ray diffraction data collected in oscillation mode

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Crystallographic R factor refinement by molecular dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900185-8

7 January 2021